ArticleGut2006
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.
Article in Gut, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- Residual bile flow shapes PPARγ-mediated antifibrotic responses in experimental segmental cholestasis.Scientific reports · 2026Article
- The ameliorative effect of pioglitazone and/or cod liver oil on hepatotoxicity induced by carbon tetrachloride in rats.Genes & nutrition · 2025Article
- Combined effects of IRAK inhibition and pioglitazone on hepatic inflammation and apoptosis in a mouse model of MASLD.Molecular biology reports · 2025Article
- Reduction in Obesity-Related Hepatic Fibrosis by SR1664.Biology · 2023Article
- A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies.Metabolites · 2022Article
- PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.International journal of molecular sciences · 2022Review
- Current treatment paradigms and emerging therapies for NAFLD/NASH.Frontiers in bioscience (Landmark edition) · 2021Review
- Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.Nature reviews. Gastroenterology & hepatology · 2021Review
- Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease.Metabolites · 2020Review
- A Selective PPARγ Modulator Reduces Hepatic Fibrosis.Biology · 2020Article
- A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease.Basic & clinical pharmacology & toxicology · 2019Review
- Too Stiff, Too Late . . . Timing Is Everything in Antiangiogenic Treatment of Liver Fibrosis.Hepatology (Baltimore, Md.) · 2019Article
- Targeting the Relaxin Pathway for Liver Disease Treatment.European medical journal. Hepatology · 2018Article
- Efficacies of rosiglitazone and retinoin on bleomycin-induced pulmonary fibrosis in rats.Experimental and therapeutic medicine · 2017Article
- Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis.World journal of gastroenterology · 2017Article
- PPARs and nonalcoholic fatty liver disease.Biochimie · 2017Review
- Novel Anti-fibrotic Therapies.Frontiers in pharmacology · 2017Review
- Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.Frontiers in pharmacology · 2015Review
- Extracellular matrix and liver disease.Antioxidants & redox signaling · 2014Review
- Pharmacological agents for NASH.Nature reviews. Gastroenterology & hepatology · 2013Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPeroxisome proliferator activated receptor gamma (PPARgamma) agonists have been shown to prevent hepatic fibrosis in rodents. We evaluated the therapeutic antifibrotic potential of the PPARgamma agonist pioglitazone on established hepatic fibrosis.
methodsRepeated injections of carbon tetrachloride (CCl4), a choline deficient diet, or bile duct ligation (BDL) were used to induce hepatic fibrosis in rats. Pioglitazone treatment was introduced at various time points. Therapeutic efficacy was assessed by comparison of the severity of hepatic fibrosis in pioglitazone treated versus untreated fibrotic controls.
resultsWhen introduced after two weeks of CCl4, pioglitazone reduced hepatic fibrosis, OH proline content, hepatic mRNA expression of collagen type I, and profibrotic genes, as well as the number of activated alpha smooth muscle actin positive hepatic stellate cells, compared with rats receiving CCl4 only, with no significant change in necroinflammation. When pioglitazone treatment was initiated after five weeks of CCl4, no antifibrotic effect was observed. Similarly, pioglitazone was associated with a reduced severity of fibrosis induced by a choline deficient diet when introduced early, while delayed treatment with pioglitazone remained ineffective. In contrast, pioglitazone failed to interrupt progression of fibrosis due to BDL, irrespective of the timing of its administration.
conclusionIn rats, the therapeutic antifibrotic efficacy of pioglitazone is limited and dependent on the type of injury, duration of disease, and/or the severity of fibrosis at the time of initiation of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.